Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: Anti-programmed cell death protein 1 and its ligand (anti-PD1/PDL1) have been proposed as a promising therapeutic option for advanced biliary tract cancer (aBTC). Given the scarce quantitative analyses of anti-PD1/PDL1 in aBTC, we thus did a meta-analysis to assess the benefits and risks...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qi, Huang, Jinsheng, Zhang, Bei, Li, Xujia, Chen, Xiuxing, Cui, Bokang, Li, Shengping, Guo, Guifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924050/
https://www.ncbi.nlm.nih.gov/pubmed/35309350
http://dx.doi.org/10.3389/fimmu.2022.801909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924050/
https://www.ncbi.nlm.nih.gov/pubmed/35309350
http://dx.doi.org/10.3389/fimmu.2022.801909

Ejemplares similares